Pfizer 5% Dextrose Injection Recalled for Potential Bag Leakage
Pfizer is recalling one lot of 5% Dextrose Injection (50 mL ADD-Vantage Units) due to lack of sterility assurance; the bags have the potential to leak. This is a Class II recall affecting 765 bags distributed nationwide.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall involving a sterility defect in an intravenous injection product. Lack of sterility assurance and potential bag leakage in an injectable pharmaceutical present significant risk of harm through contamination or compromised product integrity, meeting the Severe threshold even though no illnesses or injuries are reported in the source text.
Plain-English summary
Pfizer Inc. is recalling Lot 4923608 of 5% Dextrose Injection, USP (50 mL ADD-Vantage Units, NDC 0409-7100-68/0409-7100-66) with an expiration date of May 1, 2022. The reason for the recall is lack of sterility assurance; the bags have the potential to leak.
A total of 765 bags were distributed nationwide in the USA. Healthcare providers and patients who have received this product should check their inventory for the affected lot number and expiration date.
Patients using this product should consult their healthcare provider if they have any concerns. Healthcare facilities should review their stock of this medication and quarantine any units from the affected lot pending further instructions from Pfizer.
The recalled product
- Product
- DEXTROSE (DEXTROSE MONOHYDRATE)
- Brand
- DEXTROSE
- Manufacturer
- Pfizer Inc.
- Hazard
- sterility-defect
- bag-leakage
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Lot: 4923608 Exp. 1MAY2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same brand · DEXTROSE
- SevereDextrose Injection USP recalled due to sterility assurance concerns
FDA (Drugs) · 2026-04-29
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- SevereAtomoxetine Capsules Recalled Due to Labeling Mix-Up Error
FDA (Drugs) · 2026-05-27
- LowBusulfan Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-05-27
- SevereMG217 Multi-Symptom Treatment Cream recalled for microbial contamination
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27